• Je něco špatně v tomto záznamu ?

Robo4-mediated pancreatic endothelial integrity decreases inflammation and islet destruction in autoimmune diabetes

M. Troullinaki, LS. Chen, A. Witt, I. Pyrina, J. Phieler, I. Kourtzelis, J. Chmelar, D. Sprott, B. Gercken, M. Koutsilieris, T. Chavakis, A. Chatzigeorgiou,

. 2020 ; 34 (2) : 3336-3346. [pub] 20200109

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028551

In Type 1 Diabetes Mellitus (T1DM), leukocyte infiltration of the pancreatic islets and the resulting immune-mediated destruction of beta cells precede hyperglycemia and clinical disease symptoms. In this context, the role of the pancreatic endothelium as a barrier for autoimmunity- and inflammation-related destruction of the islets is not well studied. Here, we identified Robo4, expressed on endothelial cells, as a regulator of pancreatic vascular endothelial permeability during autoimmune diabetes. Circulating levels of Robo4 were upregulated in mice subjected to the Multiple Low-Dose Streptozotocin (MLDS) model of diabetes. Upon MLDS induction, Robo4-deficiency resulted in increased pancreatic vascular permeability, leukocyte infiltration to the islets and islet apoptosis, associated with reduced insulin levels and faster diabetes development. On the contrary, in vivo administration of Slit2 in mice modestly delayed the emergence of hyperglycaemia and ameliorated islet inflammation in MLDS-induced diabetes. Thus, Robo4-mediated endothelial barrier integrity reduces insulitis and islet destruction in autoimmune diabetes. Our findings highlight the importance of the endothelium as gatekeeper of pancreatic inflammation during T1DM development and may pave the way for novel Robo4-related therapeutic approaches for autoimmune diabetes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028551
003      
CZ-PrNML
005      
20210114154228.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1096/fj.201900125RR $2 doi
035    __
$a (PubMed)31916652
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Troullinaki, Maria $u Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
245    10
$a Robo4-mediated pancreatic endothelial integrity decreases inflammation and islet destruction in autoimmune diabetes / $c M. Troullinaki, LS. Chen, A. Witt, I. Pyrina, J. Phieler, I. Kourtzelis, J. Chmelar, D. Sprott, B. Gercken, M. Koutsilieris, T. Chavakis, A. Chatzigeorgiou,
520    9_
$a In Type 1 Diabetes Mellitus (T1DM), leukocyte infiltration of the pancreatic islets and the resulting immune-mediated destruction of beta cells precede hyperglycemia and clinical disease symptoms. In this context, the role of the pancreatic endothelium as a barrier for autoimmunity- and inflammation-related destruction of the islets is not well studied. Here, we identified Robo4, expressed on endothelial cells, as a regulator of pancreatic vascular endothelial permeability during autoimmune diabetes. Circulating levels of Robo4 were upregulated in mice subjected to the Multiple Low-Dose Streptozotocin (MLDS) model of diabetes. Upon MLDS induction, Robo4-deficiency resulted in increased pancreatic vascular permeability, leukocyte infiltration to the islets and islet apoptosis, associated with reduced insulin levels and faster diabetes development. On the contrary, in vivo administration of Slit2 in mice modestly delayed the emergence of hyperglycaemia and ameliorated islet inflammation in MLDS-induced diabetes. Thus, Robo4-mediated endothelial barrier integrity reduces insulitis and islet destruction in autoimmune diabetes. Our findings highlight the importance of the endothelium as gatekeeper of pancreatic inflammation during T1DM development and may pave the way for novel Robo4-related therapeutic approaches for autoimmune diabetes.
650    _2
$a zvířata $7 D000818
650    _2
$a apoptóza $7 D017209
650    12
$a kapilární permeabilita $7 D002199
650    _2
$a buněčné linie $7 D002460
650    _2
$a kultivované buňky $7 D002478
650    _2
$a experimentální diabetes mellitus $x metabolismus $x patologie $7 D003921
650    _2
$a diabetes mellitus 1. typu $x metabolismus $x patologie $7 D003922
650    _2
$a endoteliální buňky $x metabolismus $x patologie $7 D042783
650    _2
$a lidé $7 D006801
650    _2
$a beta-buňky $x metabolismus $x patologie $7 D050417
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a receptory buněčného povrchu $x krev $x genetika $x metabolismus $7 D011956
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chen, Lan-Sun $u Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
700    1_
$a Witt, Anke $u Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
700    1_
$a Pyrina, Iryna $u Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
700    1_
$a Phieler, Julia $u Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
700    1_
$a Kourtzelis, Ioannis $u Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
700    1_
$a Chmelar, Jindrich $u Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic.
700    1_
$a Sprott, David $u Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
700    1_
$a Gercken, Bettina $u Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
700    1_
$a Koutsilieris, Michael $u Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
700    1_
$a Chavakis, Triantafyllos $u Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Paul Langerhans Institute Dresden of the Helmholtz Center Munich, University Hospital and Faculty of Medicine, TU Dresden, Dresden, Germany. German Center for Diabetes Research (DZD), Neuherberg, Germany.
700    1_
$a Chatzigeorgiou, Antonios $u Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
773    0_
$w MED00001782 $t FASEB journal : official publication of the Federation of American Societies for Experimental Biology $x 1530-6860 $g Roč. 34, č. 2 (2020), s. 3336-3346
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31916652 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114154225 $b ABA008
999    __
$a ok $b bmc $g 1608886 $s 1119731
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 34 $c 2 $d 3336-3346 $e 20200109 $i 1530-6860 $m The FASEB journal $n FASEB J $x MED00001782
LZP    __
$a Pubmed-20210105
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace